Thomas J. Schall - 20 Oct 2022 Form 4 Insider Report for ChemoCentryx, Inc.

Role
President and CEO, Director
Signature
/s/ Susan M. Kanaya, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
20 Oct 2022
Net transactions value
$0
Form type
4
Filing time
24 Oct 2022, 19:01:29 UTC
Previous filing
08 Aug 2022
Next filing
12 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCXI Common Stock Disposed to Issuer -2,393,352 -100% 0 20 Oct 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCXI Stock Option Disposed to Issuer -4,192 -100% 0 20 Oct 2022 Common Stock 4,192 $29.83 Direct F3
transaction CCXI Stock Option Disposed to Issuer -188,408 -100% 0 20 Oct 2022 Common Stock 188,408 $29.83 Direct F3
transaction CCXI Stock Option Disposed to Issuer -2,502 -100% 0 20 Oct 2022 Common Stock 2,502 $46.59 Direct F3
transaction CCXI Stock Option Disposed to Issuer -68,998 -100% 0 20 Oct 2022 Common Stock 68,998 $46.59 Direct F3
transaction CCXI Stock Option Disposed to Issuer -7,912 -100% 0 20 Oct 2022 Common Stock 7,912 $11.02 Direct F3
transaction CCXI Stock Option Disposed to Issuer -222,088 -100% 0 20 Oct 2022 Common Stock 222,088 $11.02 Direct F3
transaction CCXI Stock Option Disposed to Issuer -11,693 -100% 0 20 Oct 2022 Common Stock 11,693 $10.86 Direct F3
transaction CCXI Stock Option Disposed to Issuer -278,307 -100% 0 20 Oct 2022 Common Stock 278,307 $10.86 Direct F3
transaction CCXI Stock Option Disposed to Issuer -262,431 -100% 0 20 Oct 2022 Common Stock 262,431 $6.62 Direct F3
transaction CCXI Stock Option Disposed to Issuer -17,569 -100% 0 20 Oct 2022 Common Stock 17,569 $6.62 Direct F3
transaction CCXI Stock Option Disposed to Issuer -285,812 -100% 0 20 Oct 2022 Common Stock 285,812 $3.57 Direct F3
transaction CCXI Stock Option Disposed to Issuer -14,188 -100% 0 20 Oct 2022 Common Stock 14,188 $3.57 Direct F3
transaction CCXI Stock Option Disposed to Issuer -406,175 -100% 0 20 Oct 2022 Common Stock 406,175 $8.19 Direct F3
transaction CCXI Stock Option Disposed to Issuer -13,825 -100% 0 20 Oct 2022 Common Stock 13,825 $8.19 Direct F3
transaction CCXI Stock Option Disposed to Issuer -8,231 -100% 0 20 Oct 2022 Common Stock 8,231 $7.10 Direct F3
transaction CCXI Stock Option Disposed to Issuer -386,769 -100% 0 20 Oct 2022 Common Stock 386,769 $7.10 Direct F3
transaction CCXI Stock Option Disposed to Issuer -7,002 -100% 0 20 Oct 2022 Common Stock 7,002 $14.28 Direct F3
transaction CCXI Stock Option Disposed to Issuer -27,998 -100% 0 20 Oct 2022 Common Stock 27,998 $14.28 Direct F3
transaction CCXI Restricted Stock Unit Disposed to Issuer -239,934 -100% 0 20 Oct 2022 Common Stock 239,934 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Thomas J. Schall is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
F2 (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
F3 Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
F4 At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.